secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2025-08-12T23:59:59+00:00
Accession:  0001178913-25-002784
Event type: earnings
Sentiment:  positive
Materiality: 0.72
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion Q2 net loss $2.5M, cash $3.5M; SIL204 shows up to 97% inhibition across KRAS cancers
--------------------------------------------------------------------------------

- Net loss $2.5M for Q2 2025 vs $1.5M in Q2 2024; operating expenses up 64.3% to $2.3M.
- Cash $3.5M at June 30, 2025 (up from $1.2M at Dec 31, 2024); warrant exercise raised ~$1.8M in July.
- Preclinical: SIL204 achieved 94% inhibition in pancreatic, 90% in colorectal, up to 97% in KRAS Q61H pancreatic cancer cells.
- Strategic collaboration with Catalent for formulation development; Phase 2/3 trial on track for H1 2026.
- Nasdaq listing maintained after 1-for-15 reverse split and panel decision; pursuing $2.5M equity threshold.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325002784/0001178913-25-002784-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891325002784/zk2533609.htm
  HTML page:      https://secwatch.observer/filing/0001178913-25-002784

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer